In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


GE Healthcare Sets Out Its Software And AI Ambitions

GE Healthcare is using its artificial intelligence platform Edison to power a new generation of medical imaging apps and devices. At the annual European Congress of Radiology (ECR), In Vivo met with Mathias Goyen, GE Healthcare’s chief medical officer, Europe, to discuss the future of AI in radiology and how technology will transform practice.

Artificial Intelligence Diagnostics Diagnostic Imaging

Virtual AI Nurses And The Future Of Chronic Disease Management

David Lee, partner at Simon-Kucher & Partners, sits down for a fireside chat with serial entrepreneur Julia Hu to talk about virtual AI nurses and the future of chronic disease management. Hu founded Lark Health in 2011 with the goal of scaling personalized, digitally driven health care to anyone in the world.

Digital Health Artificial Intelligence Innovation

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

Market Access Pharmacy Benefit Management Pricing Strategies

Podcast: Medtech Pressure Points And Opportunities In 2019

Menacing clouds on the horizon, or opportunity for medtechs large and small in the evolving health care delivery ecosystems? Probably both, and a significant amount of risk, too, for those medtechs who push through the pain barrier to, in some cases, redefine their own roles. Helping patients understand the value being created will also be a major success factor for medtechs. Whatever the outcomes, these are exciting times, says ZS' Brian Chapman, in this future-gazing podcast with In Vivo.  

Medical Device Market Access Digital Health
Advertisement

Recent Tweets from In Vivo


GETTING IT RIGHT – Drawing Together Key Stakeholders To Shape The Real-World Data Revolution

This special report reveals the challenges and solutions for early payer involvement in real-world data clinical trials, as discussed by industry leaders at a recent roundtable.

Read more
Advertisement

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Deal Of The Year 2018 Winners Announced

Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are...

Deals Growth

Does It Grow On Trees? 2018 VC Financing Trends

Last year saw some serious early-stage funding, major later stage financings and more cash filtering into seed rounds. Follow the timeline of venture capital transactions throughout 2018 worth more than $100m. A record-breaking year for biotech financing. 

Financing Growth

Hitting Refresh: Aduro CEO On Company Cuts, Pipeline Programs And Alliances

Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.

C-Suite Speaks Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship

ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope. 

C-Suite Speaks Innovation

Patient-Specificity Meets Digital Ecosystems As Corin Acquires TKR Robotics Player Omni

Hip and knee replacement challenger firm Corin Group has a big ambition to revolutionize orthopedics with connected digital ecosystems and patient-specific concepts. That aim has come a step closer with its acquisition of robotic-assisted total knee replacement (TKR) company Omni Orthopaedics. Corin's Elvio Gramignano believes this approach will lead to real change in health care delivery.       

Innovation Medical Device

Deal-Making Fires Up To Unlock Checkpoint Inhibitors’ Full Potential

Merck & Co.’s Keytruda is already elbowing its way into the top ten best-selling drugs. But it, and its expanding cohort of competitors, could be much bigger. Companies and investors are scrambling to identify the technology or technologies that can unlock checkpoint inhibitors’ potential in the 70% or more of tumors where they do not currently work. That activity is reflected across 2018’s licensing deals, M&A and financings.

ImmunoOncology Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, March 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

The Knowledge Within: An Interview With Merck KGaA’s R&D Chief

Luciano Rossetti, head of global research and development at Merck KGaA, believes the mid-sized pharma is well on its way to becoming a global immuno-oncology specialist. He discusses in-house innovation, the company’s recent IO alliance with GSK and the next wave of success that is beginning to swell across the cancer drug development community.

C-Suite Speaks Business Strategies

Building A Biotech: Industry Veteran Moroney Reflects

Simon Moroney has led the German antibody technology biotech MorphoSys since 1992. Having taken the decision to retire just as the firm is entering the next phase in its evolution, he explains to In Vivo why the time is right.

Leadership C-Suite Speaks

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Innovations In Market Access: The Will, But Not The Way?

In this In Vivo executive roundtable, an informal working group of biopharma leaders in market access reviews the current state of play with regulators, patients and payers. Contacts with the first two stakeholders are clear-eyed and surprisingly productive, but the payer remains the tie that grinds – an inscrutable partner of necessity in moving complex, costly innovations toward acceptance in the marketplace.  

Market Access Pricing Strategies

Into 2019: Regulatory Pressures Of The EU's Medical Device Regulation Will Spread Into Asia

The extra resources, time and expense that the EU Medical Device Regulation (MDR) will mean for companies in Europe has been a dominant theme since spring 2017, but the repercussions on non-European markets that rely on EU medtech legislation – in Asia, for example – are now coming to the fore, says regional medtech regulatory specialist Jack Wong. 

Asia Pacific ASEAN

Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?

Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.

Market Access Pricing Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

FDA Sticks To Its Guns On Biosimilar Naming

In the face of calls from the biosimilars industry to rethink its position on biological naming conventions as being out of step with other major territories, the FDA has issued fresh guidance that reinforces its commitment to using four-letter suffixes for both biosimilars and new brand biologics, as well as confirming that the names of any biosimilars designated as ‘interchangeable’ will bear a suffix. At the same time, the agency has rowed back on previous proposals to retroactively add a suffix to already-licensed biologics.

Biosimilars Market Intelligence

Deals Shaping The Medical Industry, March 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2019.

Deals Financing

Deals In Depth: January 2019

Genentech signed a $2.3bn alliance with Adaptive Biotechnologies around neoantigen-directed T-cell therapies. Two major players in the industry, Bristol-Myers Squibb and Celgene, agreed to combine in a $74bn deal. KKR and Viking Global Investors co-led a nearly $300m investment in genetic disease company BridgeBio Pharma.

Deals BioPharmaceutical
UsernamePublicRestriction

Register

Advertisement